Carregant...
Targeting RRM2 and Mutant BRAF is a Novel Combinatorial Strategy for Melanoma
The majority of melanoma patients harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) is relatively short-lived with progression free survival of only 6–7 months. Previously, we reported high expression of ribonucleo...
Guardat en:
| Publicat a: | Mol Cancer Res |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5025362/ https://ncbi.nlm.nih.gov/pubmed/27297629 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-16-0099 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|